Report of Foreign Issuer (6-k)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2019

Commission File Number: 001-31995

MEDICURE INC.

(Translation of registrant's name into English)

2-1250 Waverley Street 

Winnipeg, MB Canada R3T 6C6

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F x Form 40-F o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes o No x

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 8a72____.

EXHIBIT LIST

Exhibit	Title

99.1	News Release Dated August 8, 2019 - Medicure Reports Financial Results for Quarter Ended June 30, 2019

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Medicure Inc.
	(Registrant)


Date: August 8, 2019	By:	/s/ Dr. Albert D. Friesen
		Dr. Albert D. Friesen
		Title: President & CEO

Exhibit 99.1

Medicure Reports Financial Results for Quarter Ended June 30, 2019

WINNIPEG, Aug. 8, 2019 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a pharmaceutical company, today reported its results from operations for the quarter ended June 30, 2019.

Quarter Ended June 30, 2019 Highlights:

Recorded net revenue from the sale of AGGRASTAT^® (tirofiban hydrochloride) of $6.2 million during the quarter ended June 30, 2019 compared to $7.2 million for the quarter ended June 30, 2018 and $4.8 million for the quarter ended March 31, 2019;
$45.7 million in cash as at June 30, 2019;
Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA¹) for the quarter ended June 30, 2019 was $103,000 compared to adjusted EBITDA of $882,000 for the quarter ended June 30, 2018; and
Net loss for the quarter ended June 30, 2019 was $957,000 (of which, $813,000 was due to a loss from foreign exchange) compared to net income of $1.6 million for the quarter ended June 30, 2018.

Financial Results

Net revenues for the three months ended June 30, 2019 were $6.3 million compared to $7.8 million for the three months ended June 30, 2018. Net revenues from AGGRASTAT^® for the three months ended June 30, 2019 were $6.2 million compared to $7.2 million for the three months ended June 30, 2018. Additionally, ReDS^TMpoint of care system ("ReDS^TM"), contributed $51,000 of net revenue for the three months ended June 30, 2019 and the three months ended June 30, 2018 contained $606,000 of revenue from ZYPITAMAG^TM following the launch of the product in the period.

Net revenues for the six months ended June 30, 2019 were $11.2 million compared to $13.9 million for the six months ended June 30, 2018. Net revenues from AGGRASTAT^® for the six months ended June 30, 2019 were $11.0 million compared to $13.3 million for the six months ended June 30, 2018. Additionally, ReDS^TM, contributed $154,000 of net revenue for the six months ended June 30, 2019 and the six months ended June 30, 2018 contained $606,000 of revenue from ZYPITAMAG^TM following the launch of the product in the period.

The Company continued to experience strong patient market share and strong hospital demand for AGGRASTAT^® during the three and six months ended June 30, 2019, however increases in volume compared to the three and six months ended June 30, 2018 were offset by increased price competition that resulted in lower discounted prices for AGGRASTAT^®throughout the quarter.

Diversification of revenues remains an important aspect of the Company's focus with Medicure concentrating on the sales and marketing of AGGRASTAT^®, growing the sales of ZYPITAMAG^TM (pitavastatin) and marketing the ReDS^TMsystem.

Adjusted EBITDA for the three months ended June 30, 2019 was $103,000 compared to $882,000 for the three months ended June 30, 2018. The decrease in adjusted EBITDA for the three months ended June 30, 2019 is the result of the lower revenues experienced during the quarter ended June 30, 2019.

Adjusted EBITDA for the six months ended June 30, 2019 was negative $1.6 million compared to $1.8 million for the six months ended June 30, 2018. The decrease in adjusted EBITDA for the six months ended June 30, 2019 is the result of lower revenues and higher selling costs, as a result of the increase in the Company's product portfolio, experienced during the quarter ended June 30, 2019.

Net loss for the three months ended June 30, 2019 was $957,000 or $0.06 per share. This compares to net income of $1.6 million or $0.10 per share for the three months ended June 30, 2018. Net loss for the three months ended June 30, 2019 is the result of lower revenues experienced during the quarter and a foreign exchange loss relating to a decrease in the value of the U.S. dollar experienced during the quarter ended June 30, 2019.

Net loss for the six months ended June 30, 2019 was $3.7 million or $0.24 per share. This compares to net income of $3.0 million or $0.19 per share for the six months ended June 30, 2018. Net loss for the six months ended June 30, 2019 is the result of lower revenues, higher selling costs and cost of goods sold experienced during the period and a foreign exchange loss relating to a decrease in the value of the U.S. dollar experienced during the six months ended June 30, 2019.

At June 30, 2019, the Company had unrestricted cash totaling $45.7 million compared to $71.9 million of cash and short-term investments as of December 31, 2018. The decrease in cash is primarily due to the investment of U.S. $10 million made in Sensible Medical Innovations Ltd., the purchase of $3.6 million of the Company's common shares under its normal course issuer bid, a significant reduction in the Company's accounts payable and accrued liabilities and a decrease in the value of the U.S. dollar as at June 30, 2019 compared to December 31, 2018. Cash flows used in operating activities for the three months ended June 30, 2019 totaled $7.1 million.

All amounts referenced herein are in Canadian dollars unless otherwise noted.

Notes

⁽¹⁾ The Company defines EBITDA as "earnings before interest, taxes, depreciation, amortization and other income or expense" and Adjusted EBITDA as "EBITDA adjusted for non-cash and non-recurring items". The terms "EBITDA" and "Adjusted EBITDA", as it relates to the three and six months ended June 30, 2019 and 2018 results prepared using International Financial Reporting Standards ("IFRS"), do not have any standardized meaning according to IFRS. It is therefore unlikely to be comparable to similar measures presented by other companies.

Conference Call Info:

Topic: Medicure's Q2 2019 Results

Call date: Friday, August 9, 2019

Time: 7:30 AM Central Time (8:30 AM Eastern Time)

Canada toll-free: 1 (888) 465-5079 Canada toll: 1 (416) 216-4169

United States toll-free: 1 (888) 545-0687

Passcode: 7554403#

Webcast: This conference call will be webcast live over the internet and can be accessed from the Medicure investor relations page at the following link: http://www.medicure.com/investors

You may request international country-specific access information by e-mailing the Company in advance. Management will accept and answer questions related to the financial results and operations during the question-and-answer period at the end of the conference call. A recording of the call will be available following the event at the Company's website.

About Medicure

Medicure is a pharmaceutical company focused on the development and commercialization of therapies for the U.S. cardiovascular market. The present focus of the Company is the marketing and distribution of AGGRASTAT^® (tirofiban hydrochloride) injection, ZYPITAMAG^TM (pitavastatin) tablets and the ReDS™ device in the United States, where they are sold through the Company's U.S. subsidiary, Medicure Pharma Inc. For more information on Medicure please visit www.medicure.com.

To be added to Medicure's e-mail list, please visit:
http://medicure.mediaroom.com/alerts

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward Looking Information: Statements contained in this press release that are not statements of historical fact, including, without limitation, statements containing the words "believes", "may", "plans", "will", "estimates", "continues", "anticipates", "intends", "expects" and similar expressions, may constitute "forward-looking information" within the meaning of applicable Canadian and U.S. federal securities laws (such forward-looking information and forward-looking statements are hereinafter collectively referred to as "forward-looking statements"). Forward-looking statements, include, estimates, analysis and opinions of management of the Company made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors which the Company believes to be relevant and reasonable in the circumstances. Inherent in forward-looking statements are known and unknown risks, uncertainties and other factors beyond the Company's ability to predict or control that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements, and as such, readers are cautioned not to place undue reliance on forward-looking statements. Such risk factors include, among others, the Company's future product revenues, stage of development, additional capital requirements, risks associated with the completion and timing of clinical trials and obtaining regulatory approval to market the Company's products, the ability to protect its intellectual property, dependence upon collaborative partners, changes in government regulation or regulatory approval processes, and rapid technological change in the industry. Such statements are based on a number of assumptions which may prove to be incorrect, including, but not limited to, assumptions about: general business and economic conditions; the impact of changes in Canadian-US dollar and other foreign exchange rates on the Company's revenues, costs and results; the timing of the receipt of regulatory and governmental approvals for the Company's research and development projects; the availability of financing for the Company's commercial operations and/or research and development projects, or the availability of financing on reasonable terms; results of current and future clinical trials; the uncertainties associated with the acceptance and demand for new products and market competition. The foregoing list of important factors and assumptions is not exhaustive. The Company undertakes no obligation to update publicly or otherwise revise any forward-looking statements or the foregoing list of factors, other than as may be required by applicable legislation. Additional discussion regarding the risks and uncertainties relating to the Company and its business can be found in the Company's other filings with the applicable Canadian securities regulatory authorities or the US Securities and Exchange Commission, and in the "Risk Factors" section of its Form 20F for the year ended December 31, 2018.

AGGRASTAT® (tirofiban hydrochloride) is a registered trademark of Medicure International Inc.

Condensed Consolidated Interim Statements of Financial Position (expressed in thousands of Canadian dollars, except per share amounts) (unaudited)
	June 30, 2019		December 31, 2018
Assets
Current assets:
Cash and cash equivalents	$	45,705	$	24,139
Short-term investments	-		47,747
Accounts receivable	10,982		10,765
Inventories	4,911		4,239
Prepaid expenses	3,373		2,697
Total current assets	64,971		89,587
Non-current assets:
Property and equipment	908		316
Intangible assets	8,117		1,705
Holdback receivable	11,425		11,909
Investment in Sensible Medical	6,099		-
Other assets	-		117
Deferred tax assets	122		127
Total non-current assets	26,671		14,174
Total assets	$	91,642	$	103,761
Liabilities and Equity
Current liabilities:
Accounts payable and accrued liabilities	$	11,831	$	14,377
Current income taxes payable	397		1,058
Current portion of lease obligation	292		-
Current portion of royalty obligation	1,263		1,496
Total current liabilities	13,783		16,931
Non-current liabilities
Royalty obligation	1,725		2,035
Lease obligation	233		-
Other long-term liabilities	1,152		1,201
Total non-current liabilities	3,110		3,236
Total liabilities	16,893		20,167
Equity:
Share capital	117,897		122,887
Warrants	1,949		1,949
Contributed surplus	7,783		7,628
Accumulated other comprehensive income	(464)		1,268
Deficit	(52,416)		(50,138)
Total Equity	74,749		83,594
Total liabilities and equity	$	91,642	$	103,761

Condensed Consolidated Interim Statements of Net (Loss) Income and Comprehensive (Loss) Income (expressed in thousands of Canadian dollars, except per share amounts) (unaudited)
	Three months ended June 30, 2019		Three months ended June 30, 2018		Six months ended June 30, 2019		Six months ended June 30, 2018

Revenue, net	$	6,301	$	7,801	$	11,181	$	13,865
Cost of goods sold	1,353		1,202		2,391		1,991
Gross profit	4,948		6,599		8,790		11,874

Expenses
Selling	3,319		3,899		7,447		6,896
General and administrative	769		1,148		1,704		2,082
Research and development	1,181		1,071		2,102		1,980
	5,269		6,118		11,253		10,958
(Loss) income before the undernoted	(321)		481		(2,463)		916

Other income:
Revaluation of holdback receivable	-		84		-		167
	-		84		-		167

Finance costs (income):
Finance (income) expense, net	(182)		(94)		(372)		(18)
Foreign exchange loss (gain), net	813		(1,022)		1,694		(2,035)
	631		(1,116)		1,322		(2,053)
Net (loss) income before income taxes	$	(952)	$	1,681	$	(3,785)	$	3,136
Income tax (recovery) expense
Current	5		65		(72)		143
Deferred	-		21		-		39
	5		86		(72)		182
Net (loss) income	$	(957)	$	1,595	$	(3,713)	$	2,954
Other comprehensive (loss) income:
Item that may be reclassified to profit or loss
Exchange differences on translation of foreign subsidiaries	(654)		928		(1,488)		2,083

Item that will not be reclassified to profit or loss:
Revaluation of investment in Sensible Medical at FVOCI	(361)		-		(244)		-
Other comprehensive (loss) income, net of tax	(1,015)		928		(1,732)		2,083
Comprehensive (loss) income	$	(1,972)	$	2,523	$	(5,445)	$	5,037

(Loss) earnings per share
Basic	$	(0.06)	$	0.10	$	(0.24)	$	0.19
Diluted	$	(0.06)	$	0.09	$	(0.24)	$	0.17

Condensed Consolidated Interim Statements of Cash Flows (expressed in thousands of Canadian dollars, except per share amounts) (unaudited)
For the six months ended June 30	2019		2018
Cash (used in) provided by:
Operating activities:
Net (loss) income for the period	$	(3,713)	$	2,954
Adjustments for:
Current income tax (recovery) expense	(72)		143
Deferred income tax expense	-		39
Revaluation of holdback receivable	-		(167)
Amortization of property and equipment	251		48
Amortization of intangible assets	426		65
Share-based compensation	172		675
Finance (income) expense, net	(372)		(18)
Unrealized foreign exchange loss (gain)	947		(404)
Change in the following:
Accounts receivable	(1,059)		(6,297)
Inventories	(672)		(2)
Prepaid expenses	(676)		(2,117)
Accounts payable and accrued liabilities	(2,434)		4,821
Interest received, net	1,413		472
Income taxes paid	(507)		(2,041)
Royalties paid	(840)		(713)
Cash flows used in operating activities	(7,136)		(2,542)
Investing activities:
Investment in Sensible Medical	(6,337)		-
Proceeds from Apicore Sale Transaction	-		65,234
Redemptions (purchases) of short-term investments	47,747		(49,894)
Acquisition of property and equipment	(169)		(116)
Acquisition of intangible assets	(7,038)		-
Cash flows from investing activities	34,203		15,224
Financing activities:
Repurchase of common shares under normal course issuer bid	(3,592)		(1,451)
Exercise of stock options	20		256
Cash flows used in financing activities	(3,572)		(1,195)
Foreign exchange (loss) gain on cash held in foreign currency	(1,929)		520
Increase in cash and cash equivalents	21,566		12,007
Cash and cash equivalents, beginning of period	24,139		5,260
Cash and cash equivalents, end of period	$	45,705	$	17,267